Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites

Drug Safety

Volumn 38, Issue 4, 2015, Pages 373-382

  Juhlin, Kristina ^a   Karimi, Ghazaleh ^a   Andér, Maria ^a   Camilli, Sara ^b   Dheda, Mukesh ^c   Har, Tan Siew ^d   Isahak, Rokiah ^e   Lee, Su Jung ^f   Vaughan, Sarah ^g   Caduff, Pia ^a   Norén, G Niklas ^a,h  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^d Health Products Regulation Group   (Singapore)

^e MINISTRY OF HEALTH   (Malaysia)

^f National Institute of Food and Drug Safety Evaluation   (South Korea)

^g MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^h STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ALGORITHM; CLUSTER ANALYSIS; DRUG CONTAMINATION; DRUG INDUSTRY; FACTUAL DATABASE; POSTMARKETING SURVEILLANCE; PROCEDURES; STANDARDS; THERAPEUTIC EQUIVALENCE;

ALGORITHMS; CLUSTER ANALYSIS; DATABASES, FACTUAL; DRUG CONTAMINATION; DRUG INDUSTRY; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; THERAPEUTIC EQUIVALENCY;

EID: 84939999184     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0271-2     Document Type: Article

References (11)

1. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008;359(25):2674–84.
2. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457–67.
3. US Food and Drug Administration. Information on heparin. 2012. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm112597.htm. Accessed 16 Sept 2014.
4. European Medicines Agency. Questions and answers on heparins. 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500015169.pdf. Accessed 16 Sept 2014.
5. Khodabakhshi G, Juhlin K, Norén GN. Monitoring medicines (FP7 grant no 223566): D8-substandard medicines oversee a pilot project aimed at development of tools to identify reports indicating substandard medicines. 2011. http://www.monitoringmedicines.org/graphics/27523.pdf2011. Accessed 5 Feb 2015.
6. Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transperent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.
7. Medicines and Healthcare Products Regulatory Agency. Levothyroxine tablet products: a review of clinical and quality considerations. 2013. https://www.gov.uk/drug-device-alerts/drug-alert-levothyroxine-100mcg-tablets-recall-of-teva-uk-and-numark-branded-product. Accessed 11 Feb 2015.
8. González CPV, Martínez RPD, Gutiérrez JJL, Pedraza RS, Figueras A. Algorithm for the evaluation of therapeutic failure reports—proposal and pilot analysis. Pharmacoepidemiol Drug Saf. 2013;22(2):199–206.
9. US Food and Drug Administration. FDA statement on the ranbaxy atorvastatin recall. 2012. http://www.fda.gov/Drugs/DrugSafety/ucm329951.htm. Accessed 5 Feb 2015.
10. DuMouchel W, Yuen N, Payvandi N, Booth W, Rut A, Fram D. Automated method for detecting increases in frequency of spontaneous adverse event reports over time. J Biopharm Stat. 2013;23(1):161–77.
11. Norén GN. Pharmacovigilance for a revolving world: prospects of patient-generated data on the internet. Drug Saf. 2014;37(10):761–4.